IP Library Granted Patent US 10,718,022
Granted Patent B2
US 10,718,022 · App. 15/566,533 · Granted Jul 21, 2020

Compositions and methods for XI chromosome reactivation

Inventors: Michael R. Green (Boylston, MA); Sanchita Bhatnagar (Free Union, VA)
Assignee: University of Massachusetts
C12Q1/6883G01N33/5023A01K2227/10C12Q2600/156C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,718,022
App. No.
15/566,533
Granted
Jul 21, 2020
Kind
B2
Abstract

In some aspects, the disclosure relates to the reactivation of inactive X chromosomes (Xi). In some embodiments, the disclosure provides compositions and methods for the reactivation of inactive X chromosomes. In some embodiments, the compositions and methods described by the disclosure may be useful for the treatment of dominant X-linked diseases.

Claims (17)

1. A method of inducing expression of MECP2 in a mammalian cell having an inactive X chromosome, the method comprising

delivering to the cell an X chromosome inactivation factor (XCIF) inhibitor in an amount effective for inducing expression of MECP2,

wherein the XCIF inhibitor is (i) GSK650394 or EMD638683, (ii) an antisense oligomer comprising at least 8 nucleotides complementary to an mRNA encoded by SGK1, or (iii) an siRNA comprising a sequence that is complementary to an mRNA encoded by SGK1,

wherein the cell is of a subject having Rett Syndrome.

2. The method of claim 1 further comprising determining that the cell has a mutant allele of MECP2.

3. The method of claim 1 further comprising determining that delivery of the XCIF inhibitor to the cell results in

(i) induced expression of MECP2; or,

(ii) determining that an X-chromosome is reactivated; or

(iii) determining that there is decreased expression or activity of XIST.

4. The method of claim 1 , wherein the cell is in a subject.

5. The method of claim 1 , wherein the XCIF inhibitor is an siRNA that inhibits SGK1.

6. The method of claim 5 , wherein the XCIF inhibitor is an antisense oligomer that inhibits SGK1.

7. The method of claim 1 , wherein the antisense oligomer or the siRNA comprises one or more modified nucleotides and/or one or more modified internucleoside linkages.

8. The method of claim 1 , wherein the XCIF inhibitor is GSK650394.

9. The method of claim 1 , wherein the cell is a fibroblast, an embryonic stem cell, or a neuron.

10. The method of claim 1 , wherein the cell is in vitro.

11. The method of claim 1 , wherein the XCIF inhibitor is EMD638683.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2018
From: GREEN, MICHAEL R.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 045252/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2018
From: GREEN, MICHAEL R.; BHATNAGAR, SANCHITA; HOWARD HUGHES MEDICAL INSTITUTE
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 045252/0844 →
CONFIRMATORY LICENSE Recorded Oct 26, 2017
From: UNIVERSITY OF MASSACHUSETTS MEDICAL SCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044619/0307 →
Continuity (2)
Provisional Application 62148106 · Apr 15, 2015
Related Publication 20180087110A1 · Mar 29, 2018